Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07803809) titled 'Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Shanghai Minwei Biotechnology Co., Ltd
Condition:
Overweight , Obesity
Type 2 Diabetes Mellitus (T2DM)
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention:
Drug: MWN105 1
Drug: MWN105 2
Drug: MWN105 3
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: April 26, 2026
Target S...